Lisata Therapeutics, Inc.
LSTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000320017
No open-market purchases or sales by Lisata Therapeutics, Inc. insiders were filed in the last 90 days; 38 institutions reported holding it in 13F filings for Q3 2026, worth $7.55M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $9.71M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +7 vs. previous quarter
- 38
- 13F valueReported value at the end of Q3 2026
- $7.55M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $170.0K
- −83.0% year over year
- Net income, FY2025
- -$16.6M
- No comparable prior period
- Free cash flow, FY2025
- -$16.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $16.6M (9756.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 34.2K
- Shares sold short
- Change
- +5.37K
- +18.6% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding LSTA, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding LSTA at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Lisata Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 10, 2021 (view filing) | Dec 8 | 2 days | Myers Steven SDirector | PPurchase | +33.8K | $0.89 | +$30.1K | +29.9%146.8K after |
Top 10 13F holders, Q3 2026
See all 38 holdersThe largest institutional positions in Lisata Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Adage Capital Partners GP, L.L.C. | 2,487,646 | $3.58M | 0.01% | +2,487,646 | New |
| TRV GP V, LLC | 455,192 | $655.5K | 0.14% | +455,192 | New |
| Seven Fleet Capital Management LP | 371,411 | $534.8K | 0.10% | +371,411 | New |
| FCPM III Services B.V. | 297,478 | $428.4K | 0.04% | +297,478 | New |
| Vanguard Capital Management LLC | 278,837 | $401.5K | 0.00% | 00.0% | Unchanged |
| Falcon Edge Capital, LP | 183,323 | $264.0K | 0.01% | +183,323 | New |
| Sofinnova Investments, Inc. | 156,460 | $225.3K | 0.01% | +156,460 | New |
| venBio Partners LLC | 156,460 | $225.3K | 0.05% | +156,460 | New |
| Yakira Capital Management, Inc. | 135,520 | $195.1K | 0.05% | −3,041−2.2% | Reduced |
| Nantahala Capital Management, LLC | 101,221 | $145.8K | 0.01% | +101,221 | New |
Holders of 5% or more of LSTA
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Lisata Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Branham Justin Earl | 13G | 5.10%462.1K shares | New | Aug 26, 20261 filing | Aug 26, 2026 | SEC |